.



Attorneys at Law

RECEIVED CENTRAL FAX CENTER JUL 2 2 2005

Suite 2800 1100 Peachtree St. Atlanta GA 30309-4530 ι 404 815 6500 f 404 815 6555 www.KilpatrickStockton.com

direct dial 404 745 2421 direct fax 404 541 3415 SMacDonald@KilpatrickStockton.com

COMPANY/

July 22, 2005

## FAX

RECIPIENT/ PHONE NO.	FAX NO.	COMPANY/ CITY, STATE, COUNTRY
Centralized Fax Department Art Unit 1617 Examiner Jennifer M. Kim	571-273-8300	United States Patent & Trademark Office Alexandria, Virginia
Stephen C. MacDonald FROM		10 PAGES (WITH COVER)
55979-0100 REFERENCE NO		55979-314589 CLIENT/MATTER NO.

## PLEASE CALL 404 815 6497 IF YOU HAVE DIFFICULTY WITH THIS TRANSMISSION.

#### CONFIDENTIALITY NOTE:

The Information contained in this fax message is being transmitted to and is intended for the use of the individual named above. If the reader of this message is not the intended recipient, you are hereby advised that any dissemination, distribution or copy of this fax is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and destroy this fax message.

#### COMMENTS

The facsimile confirmation of the Patent Office imprinted hereon will acknowledge receipt of:

Application No: 10/621,229

Filed: July 15, 2003 Applicant: LEGARDA

For: Use of Flumazenii in the Production of a Drug for the Treatment of Alcohol

Dependency

Papers Submitted: Transmittal; Preliminary Amendment; PTO-2038

Docket No.: 55979-0100 (55979-314589)

Date Faxed: July 22, 2005

	TO BE COMPLETED BY KS OPERATIONS CENTER					
TRANSMISSION RECEIPT DATE/TIME:						
COMPLETED BY:	TOB CODE	72848				

**PATENTS** 

# IN THE U.S. PATENT AND TRADEMARK OFFICE

In re Application of:

Docket No.

55979-0100 (55979-314589)

**LEGARDA** 

Serial No. 10/621,229

Filed:

July 15, 2003

For:

Use of Flumazenii in the Production of a Drug for the Treatment of Alcohol Dependency

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED CENTRAL FAX CENTER

JUL 2 2 2005

Sir:

Transmitted herewith is a paper in the above-identified application.

Preliminary Amendment.

Applicant claims small entity status.

Form PTO-2038.

The additional fee is calculated as shown below:

					SMAL ENTI		OTHER I	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDIT. FEE	RATE	ADDIT. FEE
TOTAL	29	MINUS	20 =	9	x25	\$ 225	x50	\$
INDEP.	2	MINUS	4 <del>=</del>	0	x100	\$	x200	\$
FIRS	T PRESENTATIO TIPLE DEPENDE		3		+180	\$	+360	S
				TOTAL ADDITIONA	AL FEE	\$ 225		\$

Form PTO-2038 is attached, authorizing the charge of \$225.00.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16, or credit any overpayment, to Account No. 11-0855. A duplicate copy of this sheet is enclosed.

I hereby certify that this correspondence is being sent to the United States Patent and Trademark Office via facsimile transmission to 571-273-8300 attention Centralized Fax Department on July 22, 2005.

Stephen C. MacDonald, Ph.D. - Patent Agent

KILPATRICK STOCKTON LLP 1100 Peachtree Street; Suite 2800 Atlanta, Georgia 30309-4530

Telephone: 404/815-6500

Stephen C. MacDonald, Ph.D. - Patent Agent

Rcg. No. L0063

# RECEIVED CENTRAL FAX CENTER

JUL 2 2 2005

PATENTS

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	Application of:	)
LEGA	ARDA	)
Serial	No. 10/621,229	) Art Unit: 1617
Filed:	July 15, 2003	) ) Examiner: Jennifer M. Kim
For:	Use of Flumazenil in the Production of a Drug for the Treatment of Alcohol Dependency	· · · · · · · · · · · · · · · · · · ·

### PRELIMINARY AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Prior to examination of this application, please enter the following amendment.

Amendments to the Specification begin on Page 2

Amendments to the Claims begin on Page 3

Remarks begin on Page 6

07/25/2005 MBINAS 00000037 10621229

01 FC:2202

225.00 OP

Stephen C. MacDonald, Ph.D. - Rcg. No. L0063

I hereby certify that this correspondence is being sent to the United States Patent and Trademark Office via facsimile transmission to 571-273-8300 attention Centralized Fax Department on July 22, 2005.